A. Ogundele

发表

Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.

P. Jatlow, G. Friedland, Patrick F. Smith, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study

M. Labetoulle, D. Böhringer, C. Baudouin, 2018, Clinical ophthalmology.

Clinical Evaluation of an Oil-Based Lubricant Eyedrop in Dry Eye Patients with Lipid Deficiency

M. Labetoulle, D. Böhringer, C. Baudouin, 2017, European journal of ophthalmology.

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease

Rishit Zalawadia, A. Ogundele, Vinod Burade, 2020, Clinical ophthalmology.

Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension

A. Ogundele, M. Jasek, H. Maier, 2010, Clinical ophthalmology.

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits

A. Ogundele, M. Jasek, 2010, Clinical ophthalmology.

impact of topical bimatoprost 0 . 01 % and bimatoprost 0 . 03 % on conjunctival irritation in rabbits

A. Ogundele, Guangming Li, Joel J. Ellis, 2010 .

Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection

David E. Martin, Judy Doto, Patrick F. Smith, 2007, Antimicrobial Agents and Chemotherapy.

Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease

A. Mitra, Vrinda Gote, D. Pal, 2019, Pharmaceutical Research.

Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials.

P. Karpecki, J. Luchs, B. Schechter, 2019, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Impact of Hyaluronic Acid-Containing Artificial Tear Products on Reepithelialization in an In Vivo Corneal Wound Model

Eric C. Carlson, W. Kao, E. Carlson, 2018, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

The Prevalence and Incidence of Dry Eye Disease Among Patients Using Continuous Positive Airway Pressure or Other Nasal Mask Therapy Devices to Treat Sleep Apnea

Xue Song, A. Ogundele, Cynthia Matossian, 2020, Clinical ophthalmology.

Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2%

R. Sarangapani, A. Ogundele, M. Fidler, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Inhibition of Atazanavir Oral Absorption by Lansoprazole Gastric Acid Suppression in Healthy Volunteers

Patrick F. Smith, G. Morse, C. Berenson, 2006, Pharmacotherapy.

Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.

A. Ogundele, L. Trissel, C. Saenz, 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%

M. Mclaughlin, D. Earnest, A. Ogundele, 2010, Clinical ophthalmology.

A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers

A. Justice, P. Karpecki, David G. Evans, 2019, Clinical ophthalmology.

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye

A. Acs, L. Moore-Schiltz, P. Karpecki, 2019, Clinical ophthalmology.

Safety and efficacy of a hydroxypropyl guar/polyethylene glycol/propylene glycol-based lubricant eye-drop in patients with dry eye

M. Labetoulle, C. Baudouin, P. Pisella, 2016, British Journal of Ophthalmology.

Effects of a Hyaluronic Acid/Hydroxypropyl Guar Artificial Tear Solution on Protection, Recovery, and Lubricity in Models of Corneal Epithelium

Rekha Rangarajan, A. Ogundele, H. Ketelson, 2015, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.

Patrick F. Smith, A. Ogundele, B. M. Booker, 2005, Diagnostic microbiology and infectious disease.

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy

M. Hatanaka, R. Vessani, M. Jordão, 2014, Clinical ophthalmology.

Clinical Ophthalmology Dovepress Dovepress Maria Rosa Bet De Moraes Silva 4

M. Hatanaka, R. Vessani, M. Jordão, 2022 .

Compatibility of anidulafungin with other drugs during simulated Y-site administration.

A. Ogundele, L. Trissel, 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Clinical Outcomes of Fixed Versus As-Needed Use of Artificial Tears in Dry Eye Disease: A 6-Week, Observer-Masked Phase 4 Clinical Trial.

P. Asbell, A. Vingrys, L. Downie, 2018, Investigative ophthalmology & visual science.

Using medium-fill simulation to establish a benchmark microbiological contamination rate for low-risk-level compounding.

Joseph A Gentempo, A. Ogundele, L. Trissel, 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs

A. Ogundele, L. Trissel, C. Saenz, 2002 .

Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies

P. Karpecki, J. Luchs, B. Schechter, 2019, Cornea.

Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study.

J. Sheppard, A. Justice, J. Luchs, 2019, Eye & contact lens.

Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2%

R. Sarangapani, A. Ogundele, M. Fidler, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca

J. Sheppard, P. Karpecki, J. Luchs, 2021, Clinical ophthalmology.

Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease

A. Ogundele, Yang Zhao, R. Periyasamy, 2020, Clinical ophthalmology.